ReviewWorld journal of gastroenterology2014
Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Development of Prediction Model of Treatment Outcome of Helicobacter Pylori Eradication Through "One Sequencing Find All" Approach: With Whole Exome Sequencing for Host and Target Sequencing for Bacteria at Once
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.Journal of gastroenterology and hepatology · 2026Pooled it
- Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis.Medicine · 2016Pooled it
- Application of Visual Gene Clip-Based Tailored Therapy for the Eradication ofBioMed research international · 2021Trial
- Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.World journal of gastroenterology · 2015Trial
- Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Review
- Vonoprazan-Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2026Article
- The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance.United European gastroenterology journal · 2023Article
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.Therapeutic advances in drug safety · 2023Article
- Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.Digestive diseases and sciences · 2022Review
- Tailored eradication strategyWorld journal of gastroenterology · 2021Article
- Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.Oncotarget · 2021Review
- Can Aminoglycosides Be Used as a New Treatment forInfection & chemotherapy · 2019Article
- CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy forWorld journal of clinical cases · 2018Article
- Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Expert opinion on drug metabolism & toxicology · 2018Review
- Effectiveness ofPrzeglad gastroenterologiczny · 2018Article
- Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment forThe American journal of tropical medicine and hygiene · 2017Article
- Importance of antimicrobial susceptibility testing for the management of eradication inWorld journal of gastroenterology · 2017Review
- Institutional profile: University of Florida Health Personalized Medicine Program.Pharmacogenomics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cure rates of Helicobacter pylori (H. pylori) eradication therapy using a proton pump inhibitor (PPI) and antimicrobial agents such as amoxicillin, clarithromycin, and metronidazole are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of the inhibition of acid secretion. Annual cure rates have gradually decreased because of the increased prevalence of H. pylori strains resistant to antimicrobial agents, especially to clarithromycin. Alternative regimens have therefore been developed incorporating different antimicrobial agents. Further, standard PPI therapy (twice-daily dosing) often fails to induce a long-term increase in intragastric pH > 4.0. Increasing the eradication rate requires more frequent and higher doses of PPIs. Therapeutic efficacy related to acid secretion is influenced by genetic factors such as variants of the genes encoding drug-metabolizing enzymes (e.g., cytochrome P450 2C19, CYP2C19), drug transporters (e.g., multidrug resistance protein-1; ABCB1), and inflammatory cytokines (e.g., interleukin-1β). For example, quadruple daily administration of PPI therapy potently inhibits acid secretion within 24 h, irrespective of CYP2C19 genotype. Therefore, tailored H. pylori eradication regimens that address acid secretion and employ optimal antimicrobial agents based on results of antimicrobial agent-susceptibility testing may prove effective in attaining higher eradication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.